Overview

MannKind Corporation (Nasdaq:MNKD) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, AFREZZA® , is an ultra rapid-acting insulin. AFREZZA is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia.

Featured Links


Receive E-mail AlertsE-mail Alert Icon
Alerts are e-mailed to you whenever certain new company information is posted to this site.
Sign-up Now!
MNKD (Common Stock)
ExchangeNASDAQ GM (US Dollar)
Price$5.39
Change (%) Stock is Down 0.14 (2.53%)
Volume3,624,000
Data as of 10/22/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore Press Releases
DateTitle 
09/29/14MannKind Announces Receipt of $150 Million Licensing Upfront Payment
VALENCIA, Calif., Sept. 29, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced that it had received a $150 million upfront payment in connection with an exclusive worldwide collaboration and licensing agreement with Sanofi for development and commercialization of Afrezza® (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes. About MannKind Corporation MannKind Corporation (Nasdaq:MNKD) focuses on... 
Printer Friendly Version
09/24/14MannKind Announces Closing of Global Licensing Agreement With Sanofi
VALENCIA, Calif., Sept. 24, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced the closing of a worldwide exclusive collaboration and licensing agreement with Sanofi for development and commercialization of Afrezza® (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes. The closing follows completion of the US Federal Trade Commission's review of the transaction under the Hart-Scott-Rodino Act and the co... 
Printer Friendly Version
09/02/14MannKind Corporation to Present at Morgan Stanley Global Healthcare Conference
VALENCIA, Calif., Sept. 2, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing therapeutic products for diabetes, announced today that it will present at The Morgan Stanley Global Healthcare Conference on Tuesday, September 9, 2014 at 12:55 PM (ET) at the Grand Hyatt Hotel in New York City. Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company's website at ht... 
Printer Friendly Version
08/11/14Sanofi and MannKind Announce Global Licensing Agreement for Afrezza® (insulin human) Rapid-Acting Inhaled Insulin
Paris and Valencia, Calif. - August 11, 2014 - Sanofi (EURONEXT: SAN and NYSE: SNY) and MannKind Corporation (Nasdaq: MNKD) announced today that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza® (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes. The companies plan to launch Afrezza in the United States in the first quarter of 2015. Under the collabo... 
Printer Friendly Version
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.



Print Page Print | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Tear Sheet